CN117694408A

CN117694408A - Edible plant blend oil capable of reducing hyperlipidemia

Info

Publication number: CN117694408A
Application number: CN202410048746.3A
Authority: CN
Inventors: 吴港城; 崔茹; 朱云; 张晖; 金青哲; 王兴国
Original assignee: Jiangnan University
Current assignee: Jiangnan University
Priority date: 2024-01-12
Filing date: 2024-01-12
Publication date: 2024-03-15

Abstract

The invention provides edible plant blend oil for reducing hyperlipidemia, which belongs to the field of oil nutrition, and comprises 6-8% of GLA, 8-20% of DAG, 8-16% of MLCT and 3.25-6.5% of ALA in percentage by weight of various raw materials; the food plant blend oil provided by the invention is reasonable in collocation, and the synergistic effect between lipid concomitants is utilized, so that the food plant blend oil can achieve the effect of reducing blood fat, meets the expectations of consumers for healthy plant oil, and has good application value and market prospect; the invention does not contain any antioxidant and is prepared by blending pure natural edible oil.

Description

Edible plant blend oil capable of reducing hyperlipidemia

Technical Field

The invention belongs to the field of grease nutrition, and particularly relates to edible plant blend oil capable of reducing hyperlipidemia.

Background

Hyperlipidemia is a complex and persistent metabolic disorder that has posed a major threat to human health. The early stages of hyperlipidemia are usually free of obvious clinical symptoms, but their damage to the body is hidden, systemic. When endogenous lipid metabolism is disturbed or exogenous lipid is taken too much, blood lipid composition is markedly abnormal, and hyperlipidemia is formed. Hyperlipidemia including disturbed glycolipid metabolism and systemic homeostasis is a high risk factor for metabolic diseases such as obesity, diabetes, nonalcoholic fatty liver disease, and cardiovascular disease. However, the traditional medicines for the disease, such as phenoxyacetic acid, antioxidants, statins and the like, have certain side effects after being taken for a long time. Therefore, the development of green, healthy natural foods instead of traditional medicines is one of the methods for intervention in hyperlipidemia in the future, and the regulation of diet is also the most direct way to intervene or prevent diseases.

The grease is one of three essential nutrients for human body, mainly comprises triglyceride and trace active accompanying substances, can provide energy and essential fatty acid for the human body, and is vital to the healthy development of the human body. Such as gamma-linolenic acid (GLA), essential fatty acid of human body, can prevent fatty acid oxidation, and has blood lipid reducing effect; and GLA and derivative molecules thereof can also influence the expression of various genes involved in immune functions and apoptosis, and inhibit the tumor cell cycle process and tumor cell angiogenesis. Alpha-linolenic acid (ALA) can regulate blood lipid and blood sugar, reduce cholesterol, triglyceride, LDL and VLDL, raise HDL, and exert antithrombotic effect. Because a single oil is difficult to be rich in multiple nutritional ingredients, the vegetable blend oil is generated in order to make the edible oil more comprehensive in nutrition.

The relationship between edible oil and fat metabolism has shown that polyunsaturated fatty acids have a profound effect on liver fatty acid metabolism. This is probably because the physiological activity of dietary fat rich in polyunsaturated fatty acids affects serum and tissue lipid levels; borage oil (BSO) not only contains various active ingredients, but also contains GLA, and can play a role in reducing blood fat. The ALA-rich oil can reduce cholesterol and regulate lipid metabolism.

The Diglyceride (DAG) is a product obtained by esterifying two fatty acids in oil with glycerol (glycerin), and is simply called diglyceride or diglyceride. It has been shown that DAG has important functions in reducing excess fat in viscera, reducing blood esters in the body, inhibiting body weight gain, etc., and this function is achieved mainly by inhibiting accumulation of Triglycerides (TG) in the body by such substances.

MLCT is a novel class of structural lipids formed from the binding of medium carbon chain fatty acids (MCFA) and long carbon chain fatty acids (LCFA) to the same glycerol molecule. MLCT has great significance in controlling weight, body fat and improving metabolism of apolipoprotein, and is a health food for preventing and controlling obesity and other chronic diseases. Nowadays, the consumption level of people is increased, and the diseases related to fat digestion, absorption, metabolism and the like are increased, and research and discovery of high fat diet is usually accompanied by diseases such as obesity, diabetes, hyperlipidemia, certain cancers and the like, so people are focusing on modifying natural fat to produce medium-long carbon chain triglyceride (MLCT) so as to achieve the purpose of healthy diet.

At present, research on edible vegetable blend oils has not focused on different fatty acid glyceride restrictions. For example, chinese patent CN201911125017.9 discloses a blood lipid-lowering oil and a preparation method thereof, which selects only the use of chia seed oil to provide omega-3 unsaturated fatty acids, and does not mention different fatty acid compositions and control the ratio between different fatty acids. Chinese patent CN202210165144.7 discloses a preparation method of unsaturated fatty acid with weight-reducing and lipid-lowering effects, the main component of the fatty acid obtained by the method is polyunsaturated fatty acid linoleic acid, but the proportion of fatty acid glyceride of the product is not limited and hyperlipidemia cannot be relieved. Although chinese patent CN202211225531.1 discloses a fatty acid ester compound and a preparation method thereof, the structure of the fatty acid ester compound may include fatty acyl groups formed by dehydroxylation of oleic acid, palmitoleic acid, linoleic acid, linolenic acid, stearic acid, arachidonic acid, eicosatetraenoic acid, eicosapentaenoic acid or docosahexaenoic acid, there is still no limitation on the proportion of different fatty acid glycerides and no effect of reducing hyperlipidemia.

Disclosure of Invention

This section is intended to outline some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section as well as in the description summary and in the title of the application, to avoid obscuring the purpose of this section, the description summary and the title of the invention, which should not be used to limit the scope of the invention.

The present invention has been made in view of the above and/or problems occurring in the prior art.

Therefore, the invention aims to overcome the defects in the prior art and provide the edible plant blend oil with the function of reducing the hyperlipidemia.

In order to solve the technical problems, the invention provides the following technical scheme: an edible vegetable blend oil with the function of reducing hyperlipidemia, wherein the content of fatty acid glycerol in a finished product is calculated by percentage, and the blend oil comprises 6-8% of GLA from borage, evening primrose and blackcurrant seed oil, 8-20% of DAG from soybean oil, peanut oil and rapeseed oil, 8-16% of MLCT from coconut oil and palm oil, and 3.25-6.5% of ALA from chia seeds, perilla seeds, flax seeds and peony seed oil.

As a preferable scheme of the plant blend oil, the invention comprises the following steps: fatty acid glycerides contained in the blend oil composition: GLA, DAG, MLCT, ALA are not exogenously added.

As a preferable scheme of the plant blend oil, the invention comprises the following steps: the edible plant blend oil comprises borage oil, evening primrose oil, blackcurrant seed oil, diglyceride oil, medium-long chain triglyceride oil, chia seed oil, perilla seed oil, linseed oil and peony seed oil.

As a preferable scheme of the plant blend oil, the invention comprises the following steps: the blend oil is not specified for the fatty acid glyceride content, but defines the numerical ranges of GLA 6.9%, DAG 10%, MLCT 14% and ALA 4.95%.

Still another object of the present invention is to overcome the deficiencies in the prior art and to provide a method for preparing edible vegetable blend oil with reduced hyperlipidemia, comprising,

and mixing the nutritional oil according to a proportion at room temperature, fully stirring to obtain mixed oil, and further filtering to obtain a product.

As a preferable scheme of the preparation method of the plant blend oil, the invention comprises the following steps: the stirring speed is 65r/min, the stirring time is 25min, and the filtering is 300 mesh filtering.

The invention further aims to overcome the defects in the prior art and provide the application of the edible plant blend oil with the function of reducing the hyperlipidemia in preparing the formula food with special medical application for patients with the hyperlipidemia.

The invention has the beneficial effects that:

(1) The invention provides edible plant blend oil with blood fat reducing function, which comprises the following raw materials, by weight, 6-8% of GLA, 8-20% of DAG, 8-16% of MLCT and 3.25-6.5% of ALA; wherein, the fatty acid such as GLA, DAG, MLCT, ALA and the like are not exogenously added.

(2) The food plant blend oil provided by the invention is reasonable in collocation, and the synergistic effect between lipid concomitants is utilized, so that the food plant blend oil can achieve the effect of reducing blood fat, meets the expectations of consumers for healthy plant oil, and has good application value and market prospect; the invention does not contain any antioxidant and is prepared by blending pure natural edible oil.

(3) The fatty acid composition with good fat component can rapidly provide energy, and unsaturated fatty acid has antioxidant capacity, so that the degree of attack of cells by free radicals can be relieved; the blend oil contains MLCT, is a nutrient substance with special physiological functions, has a unique metabolic pathway in human body, can provide energy, and has the functions of inhibiting fat accumulation in the body, improving intestinal morphology and structure, regulating immunity, preventing and treating diseases and the like; DAG is a trace component of natural vegetable oil and fat, is a well-known and safe food component, and has positive effects in inhibiting accumulation of neutral fat, relieving diabetes mellitus, preventing or treating diseases caused by hyperlipidemia and cardiovascular and cerebrovascular diseases, and the like; the GLA, ALA and other unsaturated fatty acids can have good regulation effect on metabolism of human bodies, and have obvious blood fat reducing and anti-inflammatory effects. But only when GLA content is 6-8%, DAG content is 8-20%, MLCT content is 8-16%, ALA content is 3.25-6.5% can significant effect be achieved. For example, example 1, having 6.9% gla, 10% DAG, 14% MLCT and 4.95% ALA, shows the best lipid lowering effect among the selected experimental groups; an effect outside this range is poor, for example, comparative example 1, gla content is 3.75%, lower than recommended value content; in comparative example 2, the MLCT content was 6%, which was lower than the recommended value content, and from the experimental result, the lipid-lowering effect was not significant compared to example 1. This may be because different fatty acid glycerides have a synergistic effect in a certain concentration range, and the synergistic effect may be lost or antagonism may occur beyond this range, so that the effect of preventing hyperlipidemia is poor.

(4) The invention can be used as the fat component part of the special full-nutrition formula food of the formula food with special medical application for patients with hyperlipidemia, and can also be used as the fat component in the nutrient group of the non-full-nutrition formula food for patients with hyperlipidemia to be matched with other formula food with special medical application or common food; the blend oil provided by the invention does not bring any potential safety hazard to patients with hyperlipidemia.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are needed in the description of the embodiments will be briefly described below, it being obvious that the drawings in the following description are only some embodiments of the present invention, and that other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art. Wherein:

FIG. 1 is a graph showing the effect of vegetable oil blends in different proportions on weight change in mice according to the examples of the present invention.

FIG. 2 is a graph showing the effect of vegetable oil blends in different proportions on serum and liver lipid levels in mice in accordance with the examples of the present invention; wherein A is the influence of the vegetable blend oil with different proportions on the content of serum TC, B is the influence of the vegetable blend oil with different proportions on the content of serum TG, C is the influence of the vegetable blend oil with different proportions on the content of liver TC, and D is the influence of the vegetable blend oil with different proportions on the content of liver TG.

FIG. 3 is a graph showing the effect of the mixed vegetable oil in different proportions on the serum inflammatory factor of mice in the embodiment of the invention; wherein A is the influence of the vegetable blend oil with different proportions on the content of serum mouse interleukin-6 (IL-6), and B is the influence of the vegetable blend oil with different proportions on the content of serum tumor necrosis factor-alpha (TNF-alpha).

Detailed Description

In order that the above-recited objects, features and advantages of the present invention will become more apparent, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings.

In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present invention is not limited to the specific embodiments disclosed below.

Further, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic can be included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.

The edible vegetable blend oil is prepared by selecting high-quality edible vegetable oil, adding each vegetable oil into a stirring tank according to a certain proportion, stirring at the stirring speed of 65r/min for 25min at room temperature, and filtering to obtain the edible vegetable blend oil, wherein the filtering is performed by a 300-mesh screen, and the vegetable oil raw materials are all common commercial products.

Example 1

Raw materials: blackcurrant seed oil (GLA content 15%), soybean oil diglyceride oil (DAG content 40%), rapeseed oil MLCT oil (MLCT content 70%), linseed oil (ALA content 55%), and the above-mentioned high-quality edible blackcurrant seed oil 46%, diglyceride oil 25%, MLCT oil 20% and linseed oil 9% were added into a reaction kettle.

Mixing at room temperature of 25deg.C, stirring for 25min at a stirring speed of 65r/min, and filtering with 300 mesh net to obtain mixed oil.

Comparative example 1

Blend oil: high-quality edible blackcurrant seed oil 25%, diglyceride oil 46%, MLCT oil 20% and linseed oil 9% are selected and added into a reaction kettle.

The difference is that: the GLA content provided by the blend oil is lower than the recommended range of the patent.

Comparative example 2

Blend oil: the high-quality edible blackcurrant seed oil 46%, diglyceride oil 15%, soybean oil 10%, MLCT oil 20% and linseed oil 9% are selected and added into a reaction kettle.

The difference is that: the content of the diglyceride provided by the blend oil is lower than the recommended range of the patent, so that the consistency of the fatty acid composition of the blend oil is ensured, and soybean oil serving as the raw oil of the diglyceride is used for supplementing. Mixing at room temperature of 25deg.C, stirring for 25min at a stirring speed of 65r/min, and filtering with 300 mesh net to obtain mixed oil.

Comparative example 3

Blend oil: the high-quality edible blackcurrant seed oil 46%, diglyceride oil 25%, MLCT oil 8%, rapeseed oil 12% and linseed oil 9% are selected and added into a reaction kettle.

The difference is that: the MLCT content provided by the blend oil is lower than the recommended range of the patent, so that the consistency of the fatty acid composition of the blend oil is ensured, and the rapeseed oil serving as the MLCT raw oil is used for supplementing.

Comparative example 4

Blend oil: high-quality edible blackcurrant seed oil 50%, diglyceride oil 25%, MLCT oil 20% and linseed oil 5% are selected and added into a reaction kettle.

The difference is that: the ALA content provided by the blend oil is lower than the recommended range of the patent. Mixing at room temperature of 25deg.C, stirring for 25min at a stirring speed of 65r/min, and filtering with 300 mesh net to obtain mixed oil.

Comparative example 5

Blend oil: high-quality edible blackcurrant seed oil 55%, diglyceride oil 30%, MLCT oil 23% and linseed oil 10% are selected and added into a reaction kettle.

The difference is that: the GLA content provided by the blend oil is higher than the recommended range of the patent. Mixing at room temperature of 25deg.C, stirring for 25min at a stirring speed of 65r/min, and filtering with 300 mesh net to obtain mixed oil.

Comparative example 6

Blend oil: high-quality edible blackcurrant seed oil 29%, diglyceride oil 55%, MLCT oil 10% and linseed oil 6% are selected and added into a reaction kettle.

The difference is that: the DAG content provided by the blend oil is higher than the recommended scope of the patent. Mixing at room temperature of 25deg.C, stirring for 25min at a stirring speed of 65r/min, and filtering with 300 mesh net to obtain mixed oil.

Comparative example 7

Blend oil: selecting 44% of high-quality edible blackcurrant seed oil, 20% of diglyceride oil, 28% of MLCT oil and 8% of linseed oil, and adding into a reaction kettle.

The difference is that: the MLCT content provided by the blend oil is higher than the recommended range of the patent. Mixing at room temperature of 25deg.C, stirring for 25min at a stirring speed of 65r/min, and filtering with 300 mesh net to obtain mixed oil.

Comparative example 8

Blend oil: 40% of high-quality edible blackcurrant seed oil, 25% of diglyceride oil, 20% of MLCT oil and 15% of linseed oil are selected and added into a reaction kettle.

The difference is that: the ALA content provided by the blend oil is higher than the recommended range of the patent. Mixing at room temperature of 25deg.C, stirring for 25min at a stirring speed of 65r/min, and filtering with 300 mesh net to obtain mixed oil.

According to national standards, GLA, DAG, MLCT and ALA contents in the blend oil were detected by gas chromatography and high performance liquid chromatography, as shown in Table 1.

Table 1 percentage of essential fatty acid glycerides for each example

The invention utilizes an animal high-fat model to evaluate the lipid consumption of a C57BL6J male mouse, and the specific method is as follows:

(1) Feed oil

The blend oils of example 1 and comparative examples 1 to 8 above were prepared as experimental diets, wherein GLA, DAG, MLCT and ALA contents are shown in table 1.

(2) Grouping animals

88C 57 male mice of 4-6 weeks old were selected, 8 were randomly selected as a blank control group (CON), and the remaining 80 were subjected to high-fat modeling, and after the high-fat model was established, they were randomly divided into 11 groups of high-fat model groups (HFD), example 1 and comparative examples 1-8. Wherein, the control group mice are fed with common feed, and the high-fat group mice are fed with high-fat feed. The general feed and the high fat feed formulations are shown in tables 2 and 3.

After the mice are separated into cages, natural illumination is carried out, and the mice can eat and drink water freely; the indoor environment temperature is controlled at 22+/-2 ℃ and the humidity is about 60 percent. Mice were kept for 12 weeks, weighed 1 time a week, and weight parameters were recorded.

(3) Inspection index and processing

After the test, the mice are fasted for 12 hours, eyeballs are taken for blood collection, serum is separated (3000 r/m and centrifuged for 10 min), the mice are killed after neck breaking, the livers are rapidly taken out, quick frozen by liquid nitrogen, and the mice are stored in a freezer at-80 ℃ for standby.

(3) Preparation of liver tissue homogenate

Rinsing fresh liver tissue in pre-cooled physiological saline, removing blood, wiping the filter paper, accurately weighing 0.5g (accurate to 0.0001 g) of tissue at the same part, preparing 10% tissue homogenate (w/v) in pre-cooled sterilized physiological saline ice bath, centrifuging the tissue homogenate at 4000r/m for 10min, taking supernatant, sub-packaging, and preserving at-20 ℃ for later use.

(4) Influence of blend oil with different compositions on blood fat and liver of mice

Serum and liver samples of mice were taken and Total Cholesterol (TC) and Triglyceride (TG) levels in the serum and liver of mice were determined using a test kit.

(5) Effect of blend oils of different compositions on TNF-alpha and IL-6 in serum of hyperlipidemic mice

The mouse liver tissue supernatant is weighed, and the two factor contents of the mouse liver tissue are respectively measured according to the steps of a tumor necrosis factor-alpha (TNF-alpha) and a mouse interleukin-6 (IL-6) ELISA kit instruction book.

Table 2 general feed formulation

Table 3 high fat feed formulation

FIG. 1 shows growth curves of mice, and the establishment of a high-fat model of the mice was performed in the first 8 weeks, and the establishment of the high-fat model was successful from the eighth week. The mice were fed with mixed vegetable oil feed in different proportions for 12 weeks. From the figure, it can be seen that the higher fat group of example 1 had significantly decreased weight, while the mice of each group of the comparative example had slightly decreased weight.

Effects of blend vegetable oils in different ratios on TC and TG content in mouse serum and liver:

as can be seen from fig. 2-a and 2-C, compared with the control group, the total cholesterol content of the high-fat building block is obviously accumulated, and after the dry state of the blend oil administration in different proportions, the total cholesterol content of the experimental group is reduced, and the total cholesterol accumulation of the experimental group is obviously improved by about 30% in the embodiment 1.

In contrast, the improvement effect of each group of the comparative examples on total cholesterol was not significant. Example 1 plant blend oil was GLA, DAG, MLCT and ALA ranges were within our limits and the proportions in the comparative groups were outside our limits. The results show that the blend oil has remarkable beneficial effects on the metabolism of serum and liver total cholesterol in mice only under the limited blend oil proportion range, and can play a role in promoting the metabolism of liver fatty acids.

Triglycerides are metabolized primarily by the liver, and high levels of triglycerides cause fatty liver-like changes, leading to increased incidence of fatty liver. As can be seen from fig. 2-B and 2-C, the triglyceride content of the modeling group was significantly accumulated compared with the control group, and the triglyceride content in the serum and liver of the mice was reduced after the administration of the blend oil in different proportions, wherein example 1 was most significant, while the TG content was not significantly affected by each of the control groups. The blend oil of example 1 showed the most remarkable improvement effect on TG accumulation, indicating that the fatty acid composition ratio had a positive effect on lipid metabolism. Compared with example 1, the GLA, DAG, MLCT and ALA ranges in the comparative examples are outside the range defined by the patent, so that the TG relieving effect is poor, and only GLA, DAG, MLCT and ALA components are in the proportion range defined by the patent from the side.

TNF-alpha and IL-6 are pro-inflammatory factors, and the content of the pro-inflammatory factors can primarily reflect the inflammatory change condition of the organism. As shown in FIGS. 3-A and 3-B, the levels of TNF- α and IL-6 in the serum of the model group were significantly increased as compared to the control group, indicating that hyperlipidemia would lead to the occurrence of inflammatory responses in the body. The levels of TNF- α and IL-6 were significantly reduced in example 1 compared to the modeling modules, whereas the levels of TNF- α and IL-6 were not significantly reduced in the comparative examples. Because the proportion of the blend oil in each group of the comparative example is outside the proportion range defined by us, the blend oil within the limit of the patent can be obtained to obviously reduce inflammatory factors in mouse serum, thereby improving hyperlipidemia.

Taken together, GLA, DAG, MLCT and ALA components only have certain improvement effects on accumulation of TC and TG in serum and liver of mice within the limit of the patent, and can obviously relieve inflammatory response.

Comparative examples 1 to 4 were poor in lipid-lowering effect due to insufficient amounts of these active ingredients to initiate lipid-lowering signals due to the GLA, DAG, MLCT and ALA content in the blend oil being too low. In contrast, the blend oil of comparative example 5 has a GLA content exceeding the range defined in this patent, and a certain amount of GLA is passed through Δ5 desaturase to produce proinflammatory factors such as prostaglandin 2. Comparative examples 6 and 7 show that the DAG and MLCT contents are not proportional to the lipid-lowering effect, and that too high a content does not make the lipid-lowering effect more remarkable. For comparative example 8, too high an ALA content increased the unsaturated fatty acid content in the blend oil, so that oxidation occurred in the body, and the generated free radicals attack the body to produce an inflammatory reaction. Finally, GLA, DAG, MLCT and ALA contents only exert the best lipid-lowering effect within the limits defined in this patent.

It should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted without departing from the spirit and scope of the technical solution of the present invention, and it should be covered in the scope of the present invention.

Claims

1. An edible plant blend oil with the function of reducing hyperlipidemia is characterized in that: the blend oil comprises, by volume, 40-53.3% of gamma-linolenic acid GLA-derived vegetable oil, 20-50% of diglyceride DAG-derived vegetable oil, 11.43-22.86% of medium-long chain triglyceride MLCT-derived vegetable oil, and 5.9-11.81% of alpha-linolenic acid ALA-derived vegetable oil.

2. The edible vegetable blend oil with hyperlipidemia reducing function according to claim 1, wherein: the content of the fatty acid glycerol in the finished product of the blend oil is calculated by percentage, and the blend oil comprises 6-8% of GLA, 8-20% of DAG, 8-16% of MLCT and 3.25-6.5% of ALA.

3. The edible vegetable blend oil with hyperlipidemia reducing function according to claim 1, wherein: the GLA is derived from one or more of borage oil, evening primrose oil, blackcurrant seed oil and algae oil.

4. The edible vegetable blend oil with hyperlipidemia reduction function according to claim 1 or 2, wherein: the DAG-derived oil comprises one or more of camellia oil, olive oil, soybean oil, corn oil, safflower seed oil, cotton seed oil and rapeseed oil.

5. The edible vegetable blend oil with hyperlipidemia reducing function according to claim 1, wherein: the medium MLCT-derived oil comprises one or more of coconut oil extract, lauric acid triglyceride, palm kernel oil extract, capric acid triglyceride, caprylic acid triglyceride, palm oil, rice bran oil, algae oil, coconut oil, high oleic sunflower seed oil, soybean oil and rapeseed oil.

6. The edible vegetable blend oil with hyperlipidemia reducing function according to claim 1, wherein: the ALA is derived from one or more of chia seed oil, perilla seed oil, linseed oil and peony seed oil.

7. The edible vegetable blend oil with hyperlipidemia reduction function according to any one of claims 1 to 3, 5 or 6, wherein: none of the GLA, DAG, MLCT, ALA was exogenously added.

8. The method for preparing the edible plant blend oil with the function of reducing hyperlipidemia according to any one of claims 1 to 7, which is characterized in that: mixing the nutritional oil according to a proportion at room temperature, fully stirring to obtain mixed oil, and further filtering to obtain a product.

9. The method of preparing as claimed in claim 8, wherein: the stirring speed of the stirring is 65r/min, and the stirring time is 25min; the filtration was 300 mesh filtration.

10. Use of the edible vegetable blend oil with hyperlipidemia reduction function according to any one of claims 1 to 3, 5 or 6 for preparing a formulation food for special medical use for hyperlipidemia patients.